Trial Profile
Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Bortezomib
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 19 Jul 2012 Actual end date changed from Jul 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date changed from Nov 2010 to Jul 2010 as reported by ClinicalTrials.gov.
- 12 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.